The expression of GOT1 was up-regulated in pancreatic ductal adenocarcinoma (PDAC) (9–11), colorectal cancer (12, 13), breast cancer (14–16), lung adenocarcinoma (17), glioblastoma (17), prostate cancer (17–19), acute myeloid leukemia (20), and multiple myeloma (21), while down-regulated in poorly-differentiated hepatocellular carcinoma cells (22). Here, GOT1 is linked to colorectal cancer.